High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase.
Lee, M.-Y., Borgiani, P., Johansson, I., Oteri, F., Mkrtchian, S., Falconi, M., & Ingelman-Sundberg, M. (2013).
The Pharmacogenomics Journal, 14(4), 343–349.
Read the paper